人表皮生长因子受体2低表达转移性乳腺癌治疗的成本与成本效果
本研究基于Destiny-Breast04试验建立决策模型,评估HER2低表达转移性乳腺癌四种治疗序列的成本效果。T-DXd需降价41%方可使T-DXd→化疗具备成本效果。
核心结论
- 按当前价格,T-DXd对HER2低表达转移性乳腺癌不具备成本效果。
- 降价可使T-DXd具备成本效果。
- 该人群基于价值的最优序贯治疗为使用单种抗体药物偶联物而非序贯使用两种偶联物。
研究设计与样本
- 基于Destiny-Breast04试验的疾病进展和治疗数据及已发表文献的成本与生活质量数据建立决策模型。
- 模拟57岁、HER2低表达、内分泌治疗耐药、三阴性转移性乳腺癌且符合三线治疗条件的女性患者。
- 评估四种治疗序列:化疗→化疗、T-DXd→化疗、化疗→T-DXd、T-DXd→SG。
- 产出指标包括质量调整生命年(QALY)、总终生成本(2020年美元,年贴现率3%)和增量成本效果比。
- 以每获得一个额外QALY成本低于15万美元定义为成本效果。
主要发现
- 药物成本驱动各策略间的成本差异。
- 若要使T-DXd→化疗在15万美元/QALY阈值下具备成本效果,估计T-DXd需降价41%。
关键数值与推荐
- 成本效果阈值:每获得一个额外QALY成本低于15万美元。
- T-DXd→化疗在15万美元/QALY阈值下具备成本效果需T-DXd降价41%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Creating value-aligned treatment pathways in breast cancer requires understanding the cost and cost-effectiveness of new therapies. To address uncertainty in the optimal treatment sequence, we developed a decision model to assess the cost-effectiveness of various treatment sequences for patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer who are eligible for trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) under current US Food and Drug Administration labeling. METHODS: We derived disease progression and therapy data from the Destiny-Breast04 trial and sourced cost and quality-of-life data from the published literature. Our simulation modeled 57-year-old women with HER2-low, endocrine refractory, and triple-negative metastatic breast cancer eligible for third-line treatment. We evaluated four sequences: chemotherapy (chemo) → chemo, T-DXd → chemo, chemo → T-DXd, and T-DXd → SG. Outcomes included quality-adjusted life years (QALYs), total lifetime costs (2020 US dollars [USD], 3% annual discount), and incremental cost-effectiveness ratios. Sequences that cost <$150,000 USD to gain an additional QALY were considered cost effective. RESULTS: Chemo → chemo has the lowest cost at $176,000 (USD) per patient and yields 0.82 QALYs. T-DXd → chemo costs $282,000 (USD) and yields 1.08 QALYs, with an incremental cost-effectiveness ratio of $408,000 (USD) per QALY gained. T-DXd → SG costs $304,000 (USD) and yields 1.09 QALYs, with an incremental cost-effectiveness ratio of $2,200,000 (USD) per QALY gained. Drug cost drives the cost differences between each strategy. For T-DXd → chemo to be cost effective at the $150,000 (USD) per QALY threshold, we estimate that a 41% price reduction for T-DXd is needed. CONCLUSION: At its current price, T-DXd is not cost effective for HER2-low metastatic breast cancer. Price reductions can make this drug cost effective. Optimal value-based sequencing in this patient population uses a single antibody-drug conjugate rather than back-to-back conjugates.
引用
- Dickerson JC, Moen MT, Nielsen P, et al. Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer. J Clin Oncol. 2025. PMID: 40397834. doi:10.1200/JCO-24-01960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。